Replimune Group, Inc. (REPL) 10-Year Financial Performance & Capital Metrics

REPL • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutReplimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Show more

Revenue $0
EBITDA -$256M -11.3%
Net Income -$247M -14.6%
EPS (Diluted) -3.07 +5.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -62.58% -34.8%
ROIC -51.85% -24.5%
Debt/Equity 0.18 -9.6%
Interest Coverage -33.15 +6.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 21.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-45.65%

EPS CAGR

10Y-

5Y-

3Y-

TTM-15.02%

ROCE

10Y Avg-37.31%

5Y Avg-36.19%

3Y Avg-44.6%

Latest-55.89%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.26B	9.38	67	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	692.99M	4.09	10.76	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	932.87M	2.35	-1.84	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	630.68M	8.04	-2.62			-117.82%	0.18
IMNMImmunome, Inc.	2.22B	20.14	-4.03	-35.5%	-23.01%	-84.4%	0.03
NKTRNektar Therapeutics	744.1M	36.58	-4.21	9.22%	-192.87%	-141.9%	1.69
IBRXImmunityBio, Inc.	2.78B	2.82	-4.55	22.71%	-422.28%
CRVSCorvus Pharmaceuticals, Inc.	485.43M	6.50	-6.37			-21.01%	0.03

Profit & Loss

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	122K	109K	148K	0	4.14M	4.58M	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	-122K	-109K	-148K	0	-4.14M	-4.58M	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	0.11%	-0.36%	1%	-	-0.11%	1%	-	-
Operating Expenses+	8.21M	16.96M	28.42M	56.2M	78.62M	116.91M	177.08M	234.77M	261.63M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-
Selling, General & Admin	2.71M	5.71M	8.77M	17.44M	21.13M	36.26M	0	0	0
SG&A % of Revenue	-	-	-	-	-	-	-	-	-
Research & Development	6.94M	13.52M	22.17M	38.76M	57.49M	80.64M	126.53M	174.96M	189.45M
R&D % of Revenue	-	-	-	-	-	-	-	-	-
Other Operating Expenses	626K	-2.06M	451K	0	0	0	50.55M	59.81M	72.18M
Operating Income+	-9.65M	-19.23M	-30.95M	-56.2M	-82.76M	-121.48M	-177.08M	-234.77M	-261.63M
Operating Margin %	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.99%	-0.61%	-0.82%	-0.47%	-0.47%	-0.46%	-0.33%	-0.11%
EBITDA+	-9.53M	-19.12M	-30.8M	-55.66M	-78.62M	-116.91M	-174.63M	-229.69M	-255.7M
EBITDA Margin %	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-1.01%	-0.61%	-0.81%	-0.41%	-0.49%	-0.49%	-0.32%	-0.11%
D&A (Non-Cash Add-back)	122K	109K	148K	533K	4.14M	4.58M	2.45M	5.08M	5.93M
EBIT	-8.21M	-19.7M	-30.83M	-53.11M	-80.62M	-118.98M	-174.17M	-232.85M	-259.85M
Net Interest Income+	0	0	0	505K	-2.14M	-1.83M	5.85M	16.7M	13.23M
Interest Income	25K	288K	2.58M	2.42M	916K	390K	10.01M	23.36M	21.12M
Interest Expense	0	0	0	1.92M	3.06M	2.22M	4.16M	6.66M	7.89M
Other Income/Expense	1.94M	-473K	112K	3.57M	-915K	278K	3.08M	19.39M	14.8M
Pretax Income+	-7.7M	-19.7M	-30.83M	-52.63M	-83.68M	-121.21M	-174M	-215.39M	-246.83M
Pretax Margin %	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	-2.81M	-3.17M	288K	408K	468K
Effective Tax Rate %	1%	1%	1%	1%	0.97%	0.97%	1%	1%	1%
Net Income+	-7.7M	-19.7M	-30.83M	-52.63M	-80.87M	-118.04M	-174.28M	-215.79M	-247.3M
Net Margin %	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-1.56%	-0.57%	-0.71%	-0.54%	-0.46%	-0.48%	-0.24%	-0.15%
Net Income (Continuing)	-7.7M	-19.7M	-30.83M	-52.63M	-80.87M	-118.04M	-174.28M	-215.79M	-247.3M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.25	-0.64	-1.33	-1.54	-1.75	-2.26	-2.99	-3.24	-3.07
EPS Growth %	-	-1.56%	-1.08%	-0.16%	-0.14%	-0.29%	-0.32%	-0.08%	0.05%
EPS (Basic)	-0.36	-0.64	-1.33	-1.54	-1.75	-2.26	-2.99	-3.24	-3.07
Diluted Shares Outstanding	30.84M	30.84M	23.2M	34.26M	46.25M	52.21M	58.21M	66.57M	80.56M
Basic Shares Outstanding	21.51M	30.84M	23.2M	34.26M	46.25M	52.21M	58.21M	66.57M	80.56M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	22.4M	64.7M	140.98M	174.25M	483.75M	403.98M	592.6M	433.67M	495.88M
Cash & Short-Term Investments	20.59M	61.55M	134.81M	168.56M	476.3M	395.65M	583.39M	420.67M	483.8M
Cash Only	20.59M	17.58M	25.7M	59.5M	182.52M	105.95M	146.59M	74.46M	111.12M
Short-Term Investments	0	43.97M	109.11M	109.06M	293.78M	289.71M	436.8M	346.21M	372.69M
Accounts Receivable	1.41M	2.39M	2.47M	2.96M	2.95M	3.06M	2.94M	4.92M	3.73M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	6.28M	8.08M	0
Total Non-Current Assets+	417K	448K	13.35M	59.85M	59.35M	57.22M	53.99M	54.05M	55.45M
Property, Plant & Equipment	342K	370K	12.16M	58.21M	57.72M	55.58M	52.35M	52.35M	52.55M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	75K	78K	1.19M	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	1.64M	1.64M	1.64M	1.64M	1.7M	2.9M
Total Assets+	22.82M	65.15M	154.33M	234.1M	543.1M	461.19M	646.59M	487.72M	551.33M
Asset Turnover	-	-	-	-	-	-	-	-	-
Asset Growth %	-	1.86%	1.37%	0.52%	1.32%	-0.15%	0.4%	-0.25%	0.13%
Total Current Liabilities+	1.99M	5.16M	9.88M	11.87M	14.55M	20.76M	33.83M	40.44M	62.36M
Accounts Payable	323K	1.99M	7.08M	3.43M	2.35M	3.73M	5.36M	2.58M	12.46M
Days Payables Outstanding	966.35	6.67K	17.47K	-	207.68	297.74	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0
Other Current Liabilities	59K	179K	297K	2.37M	4.47M	6.89M	12.9M	17.24M	6.07M
Current Ratio	11.29x	12.53x	14.26x	14.68x	33.25x	19.46x	17.52x	10.72x	7.95x
Quick Ratio	11.29x	12.53x	14.26x	14.68x	33.25x	19.46x	17.52x	10.72x	7.95x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	32.35M	88.06M	6.58M	38.51M	29.82M	29.21M	57.47M	72.78M	73.12M
Long-Term Debt	0	0	0	9.8M	0	0	28.65M	44.81M	46.38M
Capital Lease Obligations	0	0	0	28.7M	29.82M	29.21M	28.35M	27.18M	25.8M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	32.35M	88.06M	6.58M	0	0	0	472K	786K	941K
Total Liabilities	34.33M	93.22M	16.47M	50.38M	44.37M	49.96M	91.3M	113.21M	135.49M
Total Debt+	0	0	6.56M	41.79M	33.28M	32.84M	60.76M	75.87M	76.17M
Net Debt	-20.59M	-17.58M	-19.14M	-17.71M	-149.24M	-73.11M	-85.83M	1.41M	-34.95M
Debt / Equity	-	-	0.05x	0.23x	0.07x	0.08x	0.11x	0.20x	0.18x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-29.29x	-27.05x	-54.65x	-42.57x	-35.25x	-33.15x
Total Equity+	-11.52M	-28.07M	137.86M	183.72M	498.73M	411.23M	555.29M	374.51M	415.84M
Equity Growth %	-	-1.44%	5.91%	0.33%	1.71%	-0.18%	0.35%	-0.33%	0.11%
Book Value per Share	-0.37	-0.91	5.94	5.36	10.78	7.88	9.54	5.63	5.16
Total Shareholders' Equity	-11.52M	-28.07M	137.86M	183.72M	498.73M	411.23M	555.29M	374.51M	415.84M
Common Stock	5K	5K	32K	37K	47K	47K	57K	61K	77K
Retained Earnings	-9.23M	-28.93M	-59.77M	-112.3M	-193.17M	-311.2M	-485.49M	-701.28M	-948.58M
Treasury Stock	-255K	-1.1M	0	0	0	0	0	0	0
Accumulated OCI	-2.55M	-238K	-1.05M	-982K	-394K	-973K	5.73M	4.86M	5.45M
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	-7.08M	-16.01M	-25.38M	-60.55M	-61.39M	-82.18M	-128.05M	-185.47M	-192.25M
Operating CF Margin %	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-1.26%	-0.58%	-1.39%	-0.01%	-0.34%	-0.56%	-0.45%	-0.04%
Net Income	-7.7M	-19.7M	-30.83M	-52.63M	-80.87M	-118.04M	-174.28M	-215.79M	-247.3M
Depreciation & Amortization	122K	109K	148K	533K	1.71M	2.15M	2.45M	2.65M	3.5M
Stock-Based Compensation	208K	812K	2.73M	7.74M	11.79M	24.25M	28.13M	34.13M	35.04M
Deferred Taxes	0	849K	3.74M	-945K	0	0	38K	0	0
Other Non-Cash Items	150K	26K	93K	156K	2.47M	2.22M	494K	-11.94M	-7.58M
Working Capital Changes	147K	1.89M	-1.25M	-15.41M	3.51M	7.24M	15.12M	5.48M	24.08M
Change in Receivables	-1.21M	-767K	-255K	-628K	325K	-247K	-61K	-1.92M	1.3M
Change in Inventory	0	0	255K	628K	0	247K	61K	0	0
Change in Payables	203K	1.6M	120K	-3.82M	-1.03M	1.12M	1.98M	-2.79M	9.94M
Cash from Investing+	-238K	-44.05M	-65.94M	-5.23M	-188.78M	-1.81M	-142.5M	97.2M	-23.8M
Capital Expenditures	-238K	-136K	-2.6M	-6.54M	-2.39M	-2.34M	-2.27M	-5.66M	-6.69M
CapEx % of Revenue	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	-43.91M	-63.34M	1.31K	0	530	-140.23K	0	0
Cash from Financing+	15M	54.75M	101.39M	100.17M	372.46M	6.6M	311.3M	16.28M	252.4M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	0	0	-1.95M	28.34M	96.5M	0	96.22M	0	97.27M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.32M	-16.15M	-27.98M	-67.09M	-63.78M	-84.52M	-130.32M	-191.13M	-198.94M
FCF Margin %	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-1.21%	-0.73%	-1.4%	0.05%	-0.33%	-0.54%	-0.47%	-0.04%
FCF per Share	-0.24	-0.52	-1.21	-1.96	-1.38	-1.62	-2.24	-2.87	-2.47
FCF Conversion (FCF/Net Income)	0.92x	0.81x	0.82x	1.15x	0.76x	0.70x	0.73x	0.86x	0.78x
Interest Paid	0	0	0	0	636K	0	0	3.04M	4.2M
Taxes Paid	0	0	0	0	0	55K	0	300K	105K

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-	-56.17%	-32.73%	-23.7%	-25.94%	-36.06%	-46.42%	-62.58%
Return on Invested Capital (ROIC)	-	-	-63.53%	-29.61%	-24.08%	-26.5%	-32.89%	-41.66%	-51.85%
Debt / Equity	-	-	0.05x	0.23x	0.07x	0.08x	0.11x	0.20x	0.18x
Interest Coverage	-	-	-	-29.29x	-27.05x	-54.65x	-42.57x	-35.25x	-33.15x
FCF Conversion	0.92x	0.81x	0.82x	1.15x	0.76x	0.70x	0.73x	0.86x	0.78x

Frequently Asked Questions

Growth & Financials

Replimune Group, Inc. (REPL) grew revenue by 0.0% over the past year. Growth has been modest.

Replimune Group, Inc. (REPL) reported a net loss of $310.3M for fiscal year 2025.

Dividend & Returns

Replimune Group, Inc. (REPL) has a return on equity (ROE) of -62.6%. Negative ROE indicates the company is unprofitable.

Replimune Group, Inc. (REPL) had negative free cash flow of $269.7M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

Replimune Group, Inc. (REPL) 10-Year Financial Performance & Capital Metrics

REPL • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0
EBITDA -$256M -11.3%
Net Income -$247M -14.6%
EPS (Diluted) -3.07 +5.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -62.58% -34.8%
ROIC -51.85% -24.5%
Debt/Equity 0.18 -9.6%
Interest Coverage -33.15 +6.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 21.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-45.65%

EPS CAGR

10Y-

5Y-

3Y-

TTM-15.02%

ROCE

10Y Avg-37.31%

5Y Avg-36.19%

3Y Avg-44.6%

Latest-55.89%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.26B	9.38	67	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	692.99M	4.09	10.76	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	932.87M	2.35	-1.84	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	630.68M	8.04	-2.62			-117.82%	0.18
IMNMImmunome, Inc.	2.22B	20.14	-4.03	-35.5%	-23.01%	-84.4%	0.03
NKTRNektar Therapeutics	744.1M	36.58	-4.21	9.22%	-192.87%	-141.9%	1.69
IBRXImmunityBio, Inc.	2.78B	2.82	-4.55	22.71%	-422.28%
CRVSCorvus Pharmaceuticals, Inc.	485.43M	6.50	-6.37			-21.01%	0.03

Profit & Loss

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	122K	109K	148K	0	4.14M	4.58M	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	-122K	-109K	-148K	0	-4.14M	-4.58M	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	0.11%	-0.36%	1%	-	-0.11%	1%	-	-
Operating Expenses+	8.21M	16.96M	28.42M	56.2M	78.62M	116.91M	177.08M	234.77M	261.63M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-
Selling, General & Admin	2.71M	5.71M	8.77M	17.44M	21.13M	36.26M	0	0	0
SG&A % of Revenue	-	-	-	-	-	-	-	-	-
Research & Development	6.94M	13.52M	22.17M	38.76M	57.49M	80.64M	126.53M	174.96M	189.45M
R&D % of Revenue	-	-	-	-	-	-	-	-	-
Other Operating Expenses	626K	-2.06M	451K	0	0	0	50.55M	59.81M	72.18M
Operating Income+	-9.65M	-19.23M	-30.95M	-56.2M	-82.76M	-121.48M	-177.08M	-234.77M	-261.63M
Operating Margin %	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.99%	-0.61%	-0.82%	-0.47%	-0.47%	-0.46%	-0.33%	-0.11%
EBITDA+	-9.53M	-19.12M	-30.8M	-55.66M	-78.62M	-116.91M	-174.63M	-229.69M	-255.7M
EBITDA Margin %	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-1.01%	-0.61%	-0.81%	-0.41%	-0.49%	-0.49%	-0.32%	-0.11%
D&A (Non-Cash Add-back)	122K	109K	148K	533K	4.14M	4.58M	2.45M	5.08M	5.93M
EBIT	-8.21M	-19.7M	-30.83M	-53.11M	-80.62M	-118.98M	-174.17M	-232.85M	-259.85M
Net Interest Income+	0	0	0	505K	-2.14M	-1.83M	5.85M	16.7M	13.23M
Interest Income	25K	288K	2.58M	2.42M	916K	390K	10.01M	23.36M	21.12M
Interest Expense	0	0	0	1.92M	3.06M	2.22M	4.16M	6.66M	7.89M
Other Income/Expense	1.94M	-473K	112K	3.57M	-915K	278K	3.08M	19.39M	14.8M
Pretax Income+	-7.7M	-19.7M	-30.83M	-52.63M	-83.68M	-121.21M	-174M	-215.39M	-246.83M
Pretax Margin %	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	-2.81M	-3.17M	288K	408K	468K
Effective Tax Rate %	1%	1%	1%	1%	0.97%	0.97%	1%	1%	1%
Net Income+	-7.7M	-19.7M	-30.83M	-52.63M	-80.87M	-118.04M	-174.28M	-215.79M	-247.3M
Net Margin %	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-1.56%	-0.57%	-0.71%	-0.54%	-0.46%	-0.48%	-0.24%	-0.15%
Net Income (Continuing)	-7.7M	-19.7M	-30.83M	-52.63M	-80.87M	-118.04M	-174.28M	-215.79M	-247.3M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.25	-0.64	-1.33	-1.54	-1.75	-2.26	-2.99	-3.24	-3.07
EPS Growth %	-	-1.56%	-1.08%	-0.16%	-0.14%	-0.29%	-0.32%	-0.08%	0.05%
EPS (Basic)	-0.36	-0.64	-1.33	-1.54	-1.75	-2.26	-2.99	-3.24	-3.07
Diluted Shares Outstanding	30.84M	30.84M	23.2M	34.26M	46.25M	52.21M	58.21M	66.57M	80.56M
Basic Shares Outstanding	21.51M	30.84M	23.2M	34.26M	46.25M	52.21M	58.21M	66.57M	80.56M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	22.4M	64.7M	140.98M	174.25M	483.75M	403.98M	592.6M	433.67M	495.88M
Cash & Short-Term Investments	20.59M	61.55M	134.81M	168.56M	476.3M	395.65M	583.39M	420.67M	483.8M
Cash Only	20.59M	17.58M	25.7M	59.5M	182.52M	105.95M	146.59M	74.46M	111.12M
Short-Term Investments	0	43.97M	109.11M	109.06M	293.78M	289.71M	436.8M	346.21M	372.69M
Accounts Receivable	1.41M	2.39M	2.47M	2.96M	2.95M	3.06M	2.94M	4.92M	3.73M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	6.28M	8.08M	0
Total Non-Current Assets+	417K	448K	13.35M	59.85M	59.35M	57.22M	53.99M	54.05M	55.45M
Property, Plant & Equipment	342K	370K	12.16M	58.21M	57.72M	55.58M	52.35M	52.35M	52.55M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	75K	78K	1.19M	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	1.64M	1.64M	1.64M	1.64M	1.7M	2.9M
Total Assets+	22.82M	65.15M	154.33M	234.1M	543.1M	461.19M	646.59M	487.72M	551.33M
Asset Turnover	-	-	-	-	-	-	-	-	-
Asset Growth %	-	1.86%	1.37%	0.52%	1.32%	-0.15%	0.4%	-0.25%	0.13%
Total Current Liabilities+	1.99M	5.16M	9.88M	11.87M	14.55M	20.76M	33.83M	40.44M	62.36M
Accounts Payable	323K	1.99M	7.08M	3.43M	2.35M	3.73M	5.36M	2.58M	12.46M
Days Payables Outstanding	966.35	6.67K	17.47K	-	207.68	297.74	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0
Other Current Liabilities	59K	179K	297K	2.37M	4.47M	6.89M	12.9M	17.24M	6.07M
Current Ratio	11.29x	12.53x	14.26x	14.68x	33.25x	19.46x	17.52x	10.72x	7.95x
Quick Ratio	11.29x	12.53x	14.26x	14.68x	33.25x	19.46x	17.52x	10.72x	7.95x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	32.35M	88.06M	6.58M	38.51M	29.82M	29.21M	57.47M	72.78M	73.12M
Long-Term Debt	0	0	0	9.8M	0	0	28.65M	44.81M	46.38M
Capital Lease Obligations	0	0	0	28.7M	29.82M	29.21M	28.35M	27.18M	25.8M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	32.35M	88.06M	6.58M	0	0	0	472K	786K	941K
Total Liabilities	34.33M	93.22M	16.47M	50.38M	44.37M	49.96M	91.3M	113.21M	135.49M
Total Debt+	0	0	6.56M	41.79M	33.28M	32.84M	60.76M	75.87M	76.17M
Net Debt	-20.59M	-17.58M	-19.14M	-17.71M	-149.24M	-73.11M	-85.83M	1.41M	-34.95M
Debt / Equity	-	-	0.05x	0.23x	0.07x	0.08x	0.11x	0.20x	0.18x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-29.29x	-27.05x	-54.65x	-42.57x	-35.25x	-33.15x
Total Equity+	-11.52M	-28.07M	137.86M	183.72M	498.73M	411.23M	555.29M	374.51M	415.84M
Equity Growth %	-	-1.44%	5.91%	0.33%	1.71%	-0.18%	0.35%	-0.33%	0.11%
Book Value per Share	-0.37	-0.91	5.94	5.36	10.78	7.88	9.54	5.63	5.16
Total Shareholders' Equity	-11.52M	-28.07M	137.86M	183.72M	498.73M	411.23M	555.29M	374.51M	415.84M
Common Stock	5K	5K	32K	37K	47K	47K	57K	61K	77K
Retained Earnings	-9.23M	-28.93M	-59.77M	-112.3M	-193.17M	-311.2M	-485.49M	-701.28M	-948.58M
Treasury Stock	-255K	-1.1M	0	0	0	0	0	0	0
Accumulated OCI	-2.55M	-238K	-1.05M	-982K	-394K	-973K	5.73M	4.86M	5.45M
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	-7.08M	-16.01M	-25.38M	-60.55M	-61.39M	-82.18M	-128.05M	-185.47M	-192.25M
Operating CF Margin %	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-1.26%	-0.58%	-1.39%	-0.01%	-0.34%	-0.56%	-0.45%	-0.04%
Net Income	-7.7M	-19.7M	-30.83M	-52.63M	-80.87M	-118.04M	-174.28M	-215.79M	-247.3M
Depreciation & Amortization	122K	109K	148K	533K	1.71M	2.15M	2.45M	2.65M	3.5M
Stock-Based Compensation	208K	812K	2.73M	7.74M	11.79M	24.25M	28.13M	34.13M	35.04M
Deferred Taxes	0	849K	3.74M	-945K	0	0	38K	0	0
Other Non-Cash Items	150K	26K	93K	156K	2.47M	2.22M	494K	-11.94M	-7.58M
Working Capital Changes	147K	1.89M	-1.25M	-15.41M	3.51M	7.24M	15.12M	5.48M	24.08M
Change in Receivables	-1.21M	-767K	-255K	-628K	325K	-247K	-61K	-1.92M	1.3M
Change in Inventory	0	0	255K	628K	0	247K	61K	0	0
Change in Payables	203K	1.6M	120K	-3.82M	-1.03M	1.12M	1.98M	-2.79M	9.94M
Cash from Investing+	-238K	-44.05M	-65.94M	-5.23M	-188.78M	-1.81M	-142.5M	97.2M	-23.8M
Capital Expenditures	-238K	-136K	-2.6M	-6.54M	-2.39M	-2.34M	-2.27M	-5.66M	-6.69M
CapEx % of Revenue	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	-43.91M	-63.34M	1.31K	0	530	-140.23K	0	0
Cash from Financing+	15M	54.75M	101.39M	100.17M	372.46M	6.6M	311.3M	16.28M	252.4M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	0	0	-1.95M	28.34M	96.5M	0	96.22M	0	97.27M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.32M	-16.15M	-27.98M	-67.09M	-63.78M	-84.52M	-130.32M	-191.13M	-198.94M
FCF Margin %	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-1.21%	-0.73%	-1.4%	0.05%	-0.33%	-0.54%	-0.47%	-0.04%
FCF per Share	-0.24	-0.52	-1.21	-1.96	-1.38	-1.62	-2.24	-2.87	-2.47
FCF Conversion (FCF/Net Income)	0.92x	0.81x	0.82x	1.15x	0.76x	0.70x	0.73x	0.86x	0.78x
Interest Paid	0	0	0	0	636K	0	0	3.04M	4.2M
Taxes Paid	0	0	0	0	0	55K	0	300K	105K

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-	-56.17%	-32.73%	-23.7%	-25.94%	-36.06%	-46.42%	-62.58%
Return on Invested Capital (ROIC)	-	-	-63.53%	-29.61%	-24.08%	-26.5%	-32.89%	-41.66%	-51.85%
Debt / Equity	-	-	0.05x	0.23x	0.07x	0.08x	0.11x	0.20x	0.18x
Interest Coverage	-	-	-	-29.29x	-27.05x	-54.65x	-42.57x	-35.25x	-33.15x
FCF Conversion	0.92x	0.81x	0.82x	1.15x	0.76x	0.70x	0.73x	0.86x	0.78x

Frequently Asked Questions

Growth & Financials

Replimune Group, Inc. (REPL) grew revenue by 0.0% over the past year. Growth has been modest.

Replimune Group, Inc. (REPL) reported a net loss of $310.3M for fiscal year 2025.

Dividend & Returns

Replimune Group, Inc. (REPL) has a return on equity (ROE) of -62.6%. Negative ROE indicates the company is unprofitable.

Replimune Group, Inc. (REPL) had negative free cash flow of $269.7M in fiscal year 2025, likely due to heavy capital investments.